Profile data is unavailable for this security.
About the company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
- Revenue in USD (TTM)2.78m
- Net income in USD-40.32m
- Incorporated2020
- Employees57.00
- LocationSAB Biotherapeutics Inc777 W 41St St, Suite 401MIAMI BEACH 33140United StatesUSA
- Phone+1 (305) 845-2813
- Fax+1 (302) 636-5454
- Websitehttps://www.sab.bio/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 22.49m | 8.00 | -- | 1.15 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
Ibio Inc | 225.00k | -15.44m | 22.89m | 16.00 | -- | 1.07 | -- | 101.74 | -7.74 | -10.98 | 0.0586 | 2.47 | 0.0064 | -- | 0.4907 | 14,062.50 | -44.16 | -27.69 | -69.38 | -33.13 | -- | -- | -6,863.56 | -1,862.11 | -- | -- | 0.0689 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
Aligos Therapeutics Inc | 7.97m | -75.74m | 23.40m | 68.00 | -- | 0.6842 | -- | 2.94 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Marker Therapeutics Inc | 3.73m | -10.31m | 23.47m | 8.00 | -- | 2.41 | -- | 6.30 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Gritstone bio Inc | 14.61m | -133.03m | 23.70m | 231.00 | -- | 1.07 | -- | 1.62 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Neurosense Therapeutics Ltd | 0.00 | -7.51m | 23.75m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
RenovoRx Inc | 0.00 | -8.11m | 23.97m | 8.00 | -- | 2.58 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Bolt Biotherapeutics Inc | 11.17m | -66.17m | 24.53m | 100.00 | -- | 0.2857 | -- | 2.20 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
Correlate Energy Corp | 5.65m | -34.51m | 24.57m | 19.00 | -- | -- | -- | 4.35 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.78m | -40.32m | 24.64m | 57.00 | -- | 0.5343 | -- | 8.86 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Nuo Therapeutics Inc | 1.03m | -2.69m | 24.74m | -- | -- | 40.34 | -- | 24.06 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Lisata Therapeutics Inc | 0.00 | -21.07m | 24.88m | 25.00 | -- | 0.6505 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 25.08m | 20.00 | -- | 1.95 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
Unity Biotechnology Inc | 0.00 | -27.86m | 25.10m | 19.00 | -- | 1.27 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Longeveron Inc | 1.23m | -27.90m | 26.42m | 23.00 | -- | 1.18 | -- | 21.50 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
Holder | Shares | % Held |
---|---|---|
RTW Investments LPas of 31 Mar 2024 | 917.83k | 9.95% |
BVF Partners LPas of 31 Mar 2024 | 917.83k | 9.95% |
Marshall Wace LLPas of 31 Mar 2024 | 459.17k | 4.98% |
Sessa Capital IM LPas of 13 May 2024 | 458.46k | 4.97% |
Commodore Capital LPas of 31 Mar 2024 | 183.17k | 1.99% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 175.20k | 1.90% |
Geode Capital Management LLCas of 30 Jun 2024 | 59.42k | 0.64% |
Millennium Management LLCas of 31 Mar 2024 | 54.05k | 0.59% |
Pathstone Family Office LLCas of 31 Mar 2024 | 50.65k | 0.55% |
First Manhattan Co LLCas of 31 Mar 2024 | 24.58k | 0.27% |